Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) shares, rose in value on Thursday, 05/25/23, with the stock price up by 38.41% to the previous day’s close as strong demand from buyers drove the stock to $0.40.
Actively observing the price movement in the last trading, the stock closed the session at $0.29, falling within a range of $0.30 and $0.4875. The value of beta (5-year monthly) was 0.55. Referring to stock’s 52-week performance, its high was $4.56, and the low was $0.20. On the whole, SONN has fluctuated by 62.60% over the past month.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
With the market capitalization of Sonnet BioTherapeutics Holdings Inc. currently standing at about $11.70 million, investors are eagerly awaiting this quarter’s results, scheduled for Aug 14, 2023 – Aug 18, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.3, which is expected to increase to -$0.26 for fiscal year -$1.88 and then to about -$0.95 by fiscal year 2024. Data indicates that the EPS growth is expected to be 72.50% in 2024, while the next year’s EPS growth is forecast to be 49.50%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that SONN’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
2 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 2 recommend it as a Buy and 0 called the SONN stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of SONN currently trading nearly 62.94% and 19.26% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 70.59, while the 7-day volatility ratio is showing 20.69% which for the 30-day chart, stands at 11.92%. Furthermore, Sonnet BioTherapeutics Holdings Inc. (SONN)’s beta value is 0.55, and its average true range (ATR) is 0.04. The company’s stock has been forecasted to trade at an average price of $10.35 over the course of the next 52 weeks, with a low of $6.70 and a high of $14.00. Based on these price targets, the low is -1575.0% off current price, whereas the price has to move -3400.0% to reach the yearly target high. Additionally, analysts’ median price of $10.35 is likely to be welcomed by investors because it represents a decrease of -2487.5% from the current levels.
Data on historical trading for Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) indicates that the trading volumes over the past 10 days have averaged 8.13 million and over the past 3 months, they’ve averaged 1.57 million. According to company’s latest data on outstanding shares, there are 27.48 million shares outstanding.
Nearly 0.80% of Sonnet BioTherapeutics Holdings Inc.’s shares belong to company insiders and institutional investors own 3.50% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.92 million shares as on Apr 27, 2023, resulting in a short ratio of 0.4. According to the data, the short interest in Sonnet BioTherapeutics Holdings Inc. (SONN) stood at 4.56% of shares outstanding as of Apr 27, 2023; the number of short shares registered in Mar 30, 2023 reached 0.12 million. The stock has fallen by -65.22% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SONN stock heading into the next quarter.